Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Rivaroxaban in Mild/Moderate COVID-19
NCT04757857Phase 4Terminated
- Sponsor
- Hospital Alemão Oswaldo Cruz
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital Alemão Oswaldo Cruz. Primary endpoints: Venous thromboembolic events at 30 days, Mechanical ventilation free-survival at 30 days and 2 more. Started Sep 2020; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04757857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757857.